Cystic Fibrosis

Novel therapy has positive effect on lipid uptake in cystic fibrosis patients

Published in Drug Week, October 8th, 2004

Arexis AB announced the completion of a successful phase II clinical trial around their novel human enzyme replacement therapy for the treatment of fat mal-absorption in patients with cystic fibrosis.

Cystic fibrosis is a disease involving severe fat mal-absorption due to pancreatic dysfunction that affects in excess of 100,000 patients worldwide. These patients suffer deficiencies in production of key digestive enzymes, and as a result fail to make use of important nutrients of their diet.

Arexis's study, which was conducted at Sahlgrenska University Hospital in Gothenburg, shows that if cystic fibrosis patients are supplemented with the enzyme BSSL...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-10-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry